Stocks · News reference
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
Macquarie analyst Chad Beynon maintains Ballys (NYSE:BALY) with a Neutral and raises the price target from $11 to $12.
Filed: 2026-10-02 AccNo: 0001747079-26-000092 Size: 218 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits